SSA
RXII

Schonfeld Strategic Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,000
Closed -$14K – 582
2016
Q1 		$14K Buy
+10,000
New +$14K 0.01% 298

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Schonfeld Strategic Advisors's RXII Position: Q2 2016 in Review

Schonfeld Strategic Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q2 2016, closing a stake of 10,000 shares — an estimated $14K sold.

Schonfeld Strategic Advisors first reported a position in RXII in Q1 2016 and held it in 1 quarter. The position peaked at $14K in Q1 2016. 90 funds tracked by Wall St. Rank hold RXII as of Q2 2016.

  • Schonfeld Strategic Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q2 2016 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 10,000 GALENA BIOPHARMA INC COM shares in Q2 2016, an estimated $14K.
  • Schonfeld Strategic Advisors first reported a position in GALENA BIOPHARMA INC COM in Q1 2016 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's GALENA BIOPHARMA INC COM position peaked at $14K in Q1 2016.
  • 90 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q2 2016.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.